Article
Liver Endothelium Promotes HER3-Mediated Cell Survival in Colorectal Cancer with Wild-Type and Mutant KRAS.
Molecular cancer research : MCR - 3 Jun 2022
Rathore Moeez, Zhang Wei, Wright Michel'le, Bhattacharya Rajat, Fan Fan, Vaziri-Gohar Ali, Winter Jordan, Wang Zhenghe, Markowitz Sanford D, Willis Joseph, Ellis Lee M, Wang Rui
Abstract excerpt
We previously identified that human epidermal growth factor receptor 3 (HER3, also known as ERBB3) is a key mediator in liver endothelial cell (EC) promoting colorectal cancer growth and chemoresistance, and suggested HER3-targeted therapy as a strategy for treating patients with metastatic colorectal cancer in the liver. Meanwhile, KRAS mutations occur in 40%-50% of metastatic colorectal cancer and render...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
